Combination immunotherapy plus VEGFR inhibitor for favourable risk and elderly kidney cancer patients

A study published in Clinical Genitourinary Cancer this month looks at treating patients with favourable risk metastatic renal cell carcinoma (RCC) and elderly patients with a combination of immune checkpoint inhibitors and vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). Immune checkpoint inhibitors and VEGFR inhibitors are the most commonly used medications for […]

read more

Targeted therapy dose reduction resulted in better clinical outcomes

A recent post hoc analysis of the results from the COMPARZ clinical trial, which compared first-line treatment with pazopanib versus sunitinib for metastatic renal cell carcinoma (RCC), was published in Clinical Genitourinary Cancer last February 2020. During the COMPARZ study, pazopanib and sunitinib (VEGF-TKI targeted therapy) had similar efficacy. However, this analysis showed that the […]

read more

Cabozantinib in combination with immunotherapy for advanced kidney cancer

In this video interview, Dr Monty Pal from the City of Hope cancer centre in California, USA, talks about the clinical trials involving cabozantinib in combination with atezolizumab for clear cell and non-clear cell renal cell carcinoma (RCC). Watch the video interview on Practice Update here  

read more

ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer

A retrospective analysis of data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) was presented at the American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco from 13-15 February. The analysis looked at response rates and survival of metastatic renal cell carcinoma (RCC) patients who had been treated with […]

read more

ASCO GU Cancers Symposium Highlights 2020

Over 4,000 delegates attended the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco, 13-15 February 2020. The International Kidney Cancer Coalition (IKCC) was present with a booth to raise awareness, and also attended many of the medical and patient advocacy sessions. The past couple of years have been watershed years […]

read more

ASCO GU 2020: New drug, sitravatinib in combination with nivolumab for second-line treatment of advanced kidney cancer

The results from one of the first clinical trials of a combination of a new drug, sitravatinib, with nivolumab for the second-line treatment of advanced kidney cancer were presented at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco last weekend. Sitravatinib is a type of drug called a tyrosine kinase inhibitor […]

read more

Monitoring treatment toxicities in patients with renal cell carcinoma

Drs Dan George and Tian Zhang from the Duke Prostate and Urologic Cancer Centre, Durham, USA, share their views on monitoring side effects to treatment of patients with renal cell carcinoma (RCC). Emphasis is placed on counselling patients on expectations and managing baseline co-morbidities. Maintaining a prescribed treatment schedule while focused on quality of life […]

read more

Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Immunotherapy combinations standard of care for advanced kidney cancer

In 2015, the standard treatment for most patients with advanced kidney cancer was a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) such as sunitinib or pazopanib for untreated patients, followed by a checkpoint inhibitor (PD-1 inhibitor) such as nivolumab for patients who fail treatment with a VEGF inhibitor. However, over the last several […]

read more
Showing 21 to 30 of 137 results
  TOP